The Challenge
- Traditional antibody discovery methods give limited hits and diversity
- Differentiated antibody profiles can only be found with multi-layered screening
The Single Cell Solution
- AbTheneum screens all antibodies in parallel for multiple parameters
- Sequencing the output in AbTheneum yields vast diversity due to no picking bias
Highlights
- Combine multiple screens for higher enriched data
- No picking involved - AbTheneum captures and sequences all IgG sequences, then filters down to antibodies of interest
Problem: Taking on the Challenge
Antibody discovery is a pivotal early step in drug development, but traditional methods can be inadequate to deliver differentiated antibodies. A thorough and multi-dimensional approach is necessary to ensure no stone is left unturned.
Solution: Finding a Better Way
AbTheneum is our innovative platform for single B cell antibody discovery. Unlike traditional methods,
AbTheneum screens antibodies secreted by cells within hours, without fusion or long-term culture.
How it Works
- Isolate antibody-secreting cells from millions of immune cells
- 20,000+ cells are deposited into tiny picowells, less than 200 picoliters each, for rapid screening
- Antibodies are captured on slides (Figure 1) within hours for immediate analysis, separated from cells
- Our assays operate separately from cells which allows assays without time and assay condition constraints
- Sequences of all antibodies are captured & sequenced using multiple DNA barcodes per cell in a one-of-a-kind NGS workflow
Figure 1. AbTheneum process to make antibody arrays by making a leakproof seal with Single Cell's picoliter device with one or up to four slides. Each slide can be stained with one or more fluorescent screening molecules to profile the captured antibodies. All stained slides are imaged with a fluorescent slide scanner and image analysis is incorporated into each antibody's binding profile.
Skip to the good part?
Key Advantages
Multi-layered screening
Comprehensive antibody profiling by aligning via multiple assays (Figure 2).
- Antigen binding
- Epitope specificity
- Cross-reactivity
- Receptor or ligand blocking
- Benchmark competition
- Additional custom assays available
Figure 2. All antibody scanned images from all slides are aligned.
High Fidelity Sequencing
Industry's first parallel sequencing of thousands of antibodies via a custom DNA microarray, incorporating
multiple DNA barcodes at mapped locations (Figure 3).
Figure 3. Full-length antibody sequences were clustered by clonotype, 6 diverse clonotype clusters are shown with HCDR3-LCDR3 and data from 5 screening conditions captured across 3 slides. Antibodies within sequence clonotypes show similar phenotype.
Data-Rich Output
- Full-length antibody sequences from single cells
- Cross-referenced screening data for each sequence
- Sequence liability assessments
- Germline comparisons
- Clonotype clustering
Never Miss a Clone
>98% success rate on binding antigen after expression
Fast Turnaround
AbTheneum Data Package delivered 3 weeks after harvest
Flexible and Scalable
Fresh or frozen cells
Wild type & transgenic mice, wild-type rats, rabbits, and human PBMCs
Optional antigen-specific cell isolation to increase hits (Read the case study here)
Our Experience: 10 Years of Discovery
Single Cell Technology kicked off in 2008 and has been providing antibody discovery services since 2016.
Our discoveries include therapeutic antibodies for immuno-oncology, CNS diseases, infectious disease, autoimmune conditions, and more disease areas used as monotherapies, CAR-T, and multispecific formats.
We've partnered with top 10 pharma companies and small virtual biotechs and many inbetween.
Start Your Discovery Journey